Unraveling the Cardiac Conundrum: Elucidating the Complex Interplay of Fabry Disease and its Myocardial Implications
Main Article Content
Abstract
Fabry Disease, a rare X-linked lysosomal storage disorder stemming from alpha-galactosidase A deficiency, has emerged as a multifaceted clinical enigma with profound systemic repercussions. While its multisystemic involvement is well-documented, this article delves into the intricate tapestry of Fabry Disease, focusing keenly on its cardiac implications. The myocardium, subjected to relentless glycosphingolipid deposition and subsequent cascades of molecular maladaptations, becomes a pivotal arena for clinical manifestations.
This comprehensive exploration navigates through the molecular intricacies of Fabry-related cardiac pathology, elucidating the underpinnings of ventricular hypertrophy, diastolic dysfunction, and arrhythmogenic predispositions. The interplay between endothelial dysfunction, fibrotic remodeling, and the orchestration of cellular responses within the cardiac milieu unfolds, providing a nuanced understanding of the disease's cardiovascular impact.
Furthermore, we scrutinize the evolving landscape of therapeutic interventions, ranging from conventional enzyme replacement therapy to cutting-edge gene therapies. By unraveling the complexities of Fabry Disease's cardiac manifestations, this article aspires to contribute to the refinement of clinical management strategies, offering a beacon of hope to those navigating the intricate interplay of genetic anomalies and cardiovascular compromise. As we venture into this scientific odyssey, the synthesis of molecular insights and clinical implications aims to pave the way for improved patient outcomes and the advancement of targeted therapeutic modalities.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic ). Eur Heart J. 2003;24(21): 1965-1991.
II. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124(24): 2761-2796.
III. Elliott PM, Anastasakis A, Borger M, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J. 2014;35(39):2733-2779.
IV. Charron P, Arad M, Arbustini E, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counseling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010; 31(22):2715-2726.
V. Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802-808.
VI. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005; 352(4):362-372.
VII. Wilcox WR, Oliveira JP, Hopkin RJ, et al; Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008; 93(2):112-128.
VIII. Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;
IX. 4(6):592-601.
X. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57(9):1093-1099.
XI. Politei JM, Cabrera G, Amartino H, et al. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry. Int J Clin Pract. 2013;67(1):66-72.
XII. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407-1411.
XIII. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart. 2003;89(8):929-930.
XIV. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110(9):1047-1053.